PODCAST: Nadia Harbeck about the KAITLIN study

July 2020 ASCO 2020 Marjolein Groot

In this podcast Nadia Harbeck discusses the primary analysis of the phase III KAITLIN study. This study analysed the invasive disease-free survival of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

X